Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MarketLine (a Datamonitor Company)
$50.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc Raises Low End Of Prior FY 2013 Guidance To A Range In Line With Analysts' Estimates


Thursday, 7 Nov 2013 04:01pm EST 

Emergent BioSolutions Inc revised fiscal 2013 guidance and expects total revenues in the range of $300 to $310 million, split between product revenues of $250 to $255 million and contracts and grants revenue of $50 to $55 million, and net income of $25 to $30 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $306 million and net income of $28 million for fiscal 2013. 

Related Company News

Company Quote

23.36
0.33 +1.43%
3:45pm EDT